Mr. Speaker, I have two questions.
One is that we are aware that there are some challenges with respect to testing for the presence of THC in the active bloodstream. We know that there are tests that can determine what are called the metabolites of THC. Because THC is very fat-soluble, the THC stays in the fat and then it is slowly released. Therefore, we can test the breakdown products of THC, but that is not necessarily an indicator of present impairment.
The second aspect of the question is that for people who are prescribed medicinal cannabis and are chronic users of THC, research has shown that they may have elevated levels of THC in their saliva but not be impaired.
Does my hon. colleague have any comments on how the legislation may deal with those challenges?